Pharmaxis concludes Brochitol trial
Friday, 13 June, 2008
Pharmaxis (ASX:PXS) has completed a Phase III clinical trial of its Bronchitol inhalant spray for bronchiectasis.
The 12-month trial was an open label extension to an earlier efficacy trial and was designed to determine the adverse event profile of Bronchitol following prolonged use.
Bronchiectasis is an incurable and chronic lung condition which causes excessive mucus to build up in the lungs, making breathing difficult.
Pharmaxis intends to file a marketing application for Bronchitol after the results are published in July.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
